Sorbi Flavia, Prosperi Paolo, Villanucci Alessandro, Berti Valentina, Sisti Giovanni, Fambrini Massimiliano
Department of Biomedical, Experimental and Clinical Sciences, Division of Obstetrics and Gynecology, University of Florence, Florence, Italy.
Gynecol Obstet Invest. 2015;80(4):265-71. doi: 10.1159/000366476. Epub 2015 Feb 10.
Isolated parenchymal splenic lesions are very rare and may occur as recurrences in the form of epithelial tubo-ovarian cancer (ETOC). We report a case of solitary parenchymal splenic recurrence of ETOC, which developed 50 months after the initial treatment. A 66-year-old woman underwent laparotomic primary cytoreduction in 2008. After platinum-based chemotherapy, she developed recurrences; thus, she underwent secondary and tertiary cytoreduction in 2011 and 2012 respectively. In April 2013, CT scan documented a solitary parenchymal splenic lesion and it was confirmed by FDG PET/CT. She underwent quaternary cytoreduction by laparoscopic splenectomy. Histopathological evaluation revealed metastatic parenchymal disease consistent with recurrent ETOC. She was alive and disease-free for ten months since splenectomy. In literature there are 35 cases of isolated spleen parenchymal metastasis of ETOC and our report is the first case of laparoscopic splenectomy in the setting of quaternary cytoreduction. Laparoscopic splenectomy as quaternary cytoreduction is safe and feasible and could be congruent to the well-established experiences already reported for the primary, secondary or even tertiary cytoreduction where the absence of residual disease has been translated in a significant survival benefit.
孤立性脾实质病变非常罕见,可能以上皮性输卵管卵巢癌(ETOC)复发的形式出现。我们报告一例ETOC孤立性脾实质复发病例,该病例在初始治疗50个月后出现。一名66岁女性于2008年接受剖腹探查初次肿瘤细胞减灭术。在接受铂类化疗后,她出现复发;因此,她分别于2011年和2012年接受了二次和三次肿瘤细胞减灭术。2013年4月,CT扫描发现一个孤立性脾实质病变,FDG PET/CT证实了这一病变。她接受了腹腔镜脾切除术进行四次肿瘤细胞减灭术。组织病理学评估显示转移性脾实质疾病,与复发性ETOC一致。自脾切除术后,她存活且无病生存了十个月。文献中有35例ETOC孤立性脾实质转移病例,我们的报告是首例在四次肿瘤细胞减灭术背景下进行腹腔镜脾切除术的病例。腹腔镜脾切除术作为四次肿瘤细胞减灭术是安全可行的,并且可能与已报道的关于初次、二次甚至三次肿瘤细胞减灭术的成熟经验一致,在这些手术中,无残留疾病已转化为显著的生存获益。